Creative Planning lessened its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,252 shares of the pharmaceutical company’s stock after selling 247 shares during the quarter. Creative Planning’s holdings in Vertex Pharmaceuticals were worth $705,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. We Are One Seven LLC purchased a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $32,000. Quantamental Technologies LLC acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $41,000. Hanseatic Management Services Inc. increased its holdings in shares of Vertex Pharmaceuticals by 52.0% in the fourth quarter. Hanseatic Management Services Inc. now owns 298 shares of the pharmaceutical company’s stock valued at $49,000 after purchasing an additional 102 shares during the last quarter. Stratos Wealth Partners LTD. acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $123,000. Finally, Valeo Financial Advisors LLC increased its holdings in shares of Vertex Pharmaceuticals by 18.2% in the fourth quarter. Valeo Financial Advisors LLC now owns 681 shares of the pharmaceutical company’s stock valued at $113,000 after purchasing an additional 105 shares during the last quarter. Institutional investors and hedge funds own 95.40% of the company’s stock.
In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 111,431 shares of the firm’s stock in a transaction on Monday, February 11th. The stock was sold at an average price of $180.24, for a total transaction of $20,084,323.44. Following the completion of the sale, the chief executive officer now owns 223,916 shares of the company’s stock, valued at $40,358,619.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Paul M. Silva sold 809 shares of the firm’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $186.52, for a total value of $150,894.68. Following the sale, the senior vice president now directly owns 16,896 shares of the company’s stock, valued at approximately $3,151,441.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 184,887 shares of company stock valued at $33,658,261. 0.75% of the stock is owned by insiders.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Tuesday, February 5th. The pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.24. The company had revenue of $870.11 million during the quarter, compared to analysts’ expectations of $818.29 million. Vertex Pharmaceuticals had a return on equity of 24.15% and a net margin of 68.81%. The firm’s quarterly revenue was up 33.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.61 earnings per share. As a group, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 3.22 earnings per share for the current fiscal year.
VRTX has been the subject of several recent research reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 24th. Raymond James set a $201.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 25th. HC Wainwright raised Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $220.00 price target for the company in a report on Friday, October 26th. BMO Capital Markets cut their price target on Vertex Pharmaceuticals from $204.00 to $192.00 and set an “outperform” rating for the company in a report on Thursday, October 25th. Finally, Piper Jaffray Companies cut their price target on Vertex Pharmaceuticals to $217.00 and set an “overweight” rating for the company in a report on Friday, October 26th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $203.79.
WARNING: This piece was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2019/02/14/creative-planning-decreases-stake-in-vertex-pharmaceuticals-incorporated-vrtx.html.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for treating cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for treating patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.
Featured Story: What are the components of an earnings report?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.